ClinicalTrials.gg
CompletedNCT04656561ARCHERUpdated Oct 21, 2026Results posted

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

A Phase 2 interventional study of ANX007 and Sham comparator in Geographic Atrophy, sponsored by Annexon, Inc.. Completed at 53 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Annexon, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 21, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
32nd of 107
270 · median 98
Started
2021
with 2 others
Phase 2
43 of 131
11 open now
Registered
77th of 131
by date
Lead sponsor
3 of 131
Annexon, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 32nd largest by enrollment of the 107 interventional ones that give a count, is one of 3 that started in 2021, is one of 43 in phase 2, and was the 77th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of geographic atrophy of the macula secondary to age-related macular degeneration as determined by the Investigator and confirmed by the Central Reading Center.
  • GA lesion must have the following characteristics as determined by the independent Central Reading

Center based on assessment of FAF imaging at screening:

  1. Well-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm\^2) and

    • 17.5 mm\^2.
  2. If GA is multifocal, at least 1 focal lesion must measure ≥1.25 mm\^2 with the overall aggregate area of GA as specified above.
  3. Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (that is, pattern = none) is exclusionary.
  4. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.

    • Normal luminance BCVA of 24 to 83 letters, inclusive, using ETDRS charts (20/25 to 20/320 Snellen equivalent, inclusive).
    • A female participant is eligible if she is not pregnant or breastfeeding and is a woman of non- or is using a method that is highly effective, with a failure rate of \<1% during the study intervention period and for at least 30 days after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.
  • Any evidence of choroidal neovascularization (CNV) in the study eye:

    1. Any history of CNV of any cause based on medical history.
    2. Evidence of prior or active CNV or related findings (for example, retinal pigment epithelial rips or tears) based on FAF, Spectral Domain Optical Coherence Tomography (SD-OCT) imaging, intravenous fluorescein angiography (IVFA) and color fundus photo as assessed by the Central Reading Center.
  • Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.
  • Uncontrolled glaucoma in the study eye (Intraocular pressure [IOP] >25 mmHg despite treatment with anti- glaucoma medication) or history of neovascular glaucoma.
  • History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance.
  • Any current or prior ocular disease, other than geographic atrophy, that in the opinion of the Investigator could interfere with the conduct of the study including, but not limited to, insufficient pupil dilation, retinal or optic nerve disease, media opacity, or aphakia in the study eye.
  • History of any prior IVT treatment for any indication in the study eye.
  • Any prior treatment for AMD in the study eye (for example, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    ANX007 Group 1

    ANX007 administered every month

    Drug: ANX007

  • Experimental
    ANX007 Group 2

    ANX007 administered every other month

    Drug: ANX007

  • Sham comparator
    Sham Group 3

    Sham injection administered every month

    Other: Sham comparator

  • Sham comparator
    Sham Group 4

    Sham injection administered every other month

    Other: Sham comparator

Interventions

  • DrugANX007

    Form: solution for injection; Route of Administration: IVT

  • OtherSham comparator

    Form and Route of Administration: pressure to mimic IVT injection

06

What researchers measure

Primary outcomes

  1. Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area

    GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed).

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Change From Baseline to Month 12 in GA Lesion Area

    GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.

    Time frame: Baseline to Month 12

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the investigational medicinal product. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse events module.

    Time frame: Baseline to Month 12

  3. Change From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA)

    BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

    Time frame: Baseline to Month 12

  4. Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline

    Confirmed ETDRS BCVA ≥15-letter loss was defined as ≥15-letter loss observed for 2 consecutive visits. BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

    Time frame: Baseline to Month 12

  5. Change From Baseline to Month 12 in LLVA

    LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

    Time frame: Baseline to Month 12

  6. Number of Events With ≥ 15-Letter Loss LLVA Decline

    LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

    Time frame: Baseline to Month 12

  7. Change From Baseline to Month 12 in LLVD

    LLVD as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance f 4 meters at each study visit. LL-VD will be derived by subtracting LL-BCVA from BCVA.

    Time frame: Baseline to Month 12

  8. Number of Events With ≥ 15-Letter Loss LLVD Decline

    LLVD ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVD was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

    Time frame: Baseline to Month 12

07

Results

Posted Oct 21, 2026

Participant flow

As prespecified, data were collected and reported for the participants. Therefore, the "N"s reported below = number of participants regardless of which eye was evaluated.

Participant flow — Overall Study
MilestoneANX007 EMANX007 EOMSham
Started899289
Received at least 1 dose of study drug899289
Completed737776
Not completed161513
Withdrew: Adverse event473
Withdrew: Lost to follow-up221
Withdrew: Physician decision101
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject756
Withdrew: Other than specified101
Withdrew: Death001

Outcome measures

PrimaryRate of Change (Slope) From Baseline to Month 12 in GA Lesion Area

GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area. A linear mixed effect (LME) model was used to analyze the rate of change from baseline to Month 12 GA lesion area (mm2) for all groups. The model included fixed effects of treatment, time point, treatment by time point interaction, baseline GA lesion area, baseline GA lesion area by timepoint interaction, and baseline lesion multifocality. A random intercept for participant ID and a random slope for timepoint are included to account for repeated measurements for participants. The GA lesion area was analyzed as reported (that is, not transformed).

Time frame:
Baseline to Month 12
Reported as:
Mean · mm^2/year
Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area
mm^2/yearANX007 EMANX007 EOMANX007 PooledSham
Rate of Change (Slope) From Baseline to Month 12 in GA Lesion Area1.9902 ± 0.363432.1575 ± 0.348242.0837 ± 0.301771.9019 ± 0.34239
Statistical analysis
  • ANX007 Pooled vs Sham · ANCOVA · p = 0.5503 · Slope: 0.1819
SecondaryChange From Baseline to Month 12 in GA Lesion Area

GA lesion area was assessed by fundus autofluorescence (FAF) imaging, by an independent central reading center for GA lesion area.

Time frame:
Baseline to Month 12
Reported as:
Least squares mean · mm^2
Change From Baseline to Month 12 in GA Lesion Area
mm^2ANX007 EMANX007 EOMANX007 PooledSham
Change From Baseline to Month 12 in GA Lesion Area2.3547 ± 0.264522.5782 ± 0.243172.4835 ± 0.180032.3170 ± 0.23142
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the investigational medicinal product. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse events module.

Time frame:
Baseline to Month 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsANX007 EMANX007 EOMSham
Number of Participants With Treatment Emergent Adverse Events (TEAEs)656868
SecondaryChange From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA)

BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

Time frame:
Baseline to Month 12
Reported as:
Mean · Number of letters read correctly
Change From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA)
Number of letters read correctlyANX007 EMANX007 EOMSham
Change From Baseline to Month 12 in Best Corrected Visual Acuity (BCVA)-1.7 ± 1.33-2.6 ± 1.29-4.1 ± 1.31
SecondaryNumber of Events With Confirmed ≥ 15-Letter Loss BCVA Decline

Confirmed ETDRS BCVA ≥15-letter loss was defined as ≥15-letter loss observed for 2 consecutive visits. BCVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

Time frame:
Baseline to Month 12
Reported as:
Number · Number of Events
Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline
Number of EventsANX007 EMANX007 EOMSham
Number of Events With Confirmed ≥ 15-Letter Loss BCVA Decline4815
SecondaryChange From Baseline to Month 12 in LLVA

LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

Time frame:
Baseline to Month 12
Reported as:
Least squares mean · Number of letters read correctly
Change From Baseline to Month 12 in LLVA
Number of letters read correctlyANX007 EMANX007 EOMSham
Change From Baseline to Month 12 in LLVA-1.4 ± 1.29-2.8 ± 1.25-4.8 ± 1.31
SecondaryNumber of Events With ≥ 15-Letter Loss LLVA Decline

LLVA ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVA was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

Time frame:
Baseline to Month 12
Reported as:
Number · Number of Events
Number of Events With ≥ 15-Letter Loss LLVA Decline
Number of EventsANX007 EMANX007 EOMSham
Number of Events With ≥ 15-Letter Loss LLVA Decline6816
SecondaryChange From Baseline to Month 12 in LLVD

LLVD as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance f 4 meters at each study visit. LL-VD will be derived by subtracting LL-BCVA from BCVA.

Time frame:
Baseline to Month 12
Reported as:
Least squares mean · Number of letters read correctly
Change From Baseline to Month 12 in LLVD
Number of letters read correctlyANX007 EMANX007 EOMSham
Change From Baseline to Month 12 in LLVD-0.4 ± 1.551.3 ± 1.500.6 ± 1.57
SecondaryNumber of Events With ≥ 15-Letter Loss LLVD Decline

LLVD ≥15-letter loss worsening from Baseline during the 12-month Treatment. LLVD was assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score on a test chart at a starting distance of 4 meters at each study visit. BCVA scores range from 0 to 100 letters with a higher score indicating a better vision.

Time frame:
Baseline to Month 12
Reported as:
Number · Number of Events
Number of Events With ≥ 15-Letter Loss LLVD Decline
Number of EventsANX007 EMANX007 EOMSham
Number of Events With ≥ 15-Letter Loss LLVD Decline4813

Adverse events

Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ANX007 EM2/89 (2.2%)21/89 (23.6%)21/89 (23.6%)
ANX007 EOM3/92 (3.3%)16/92 (17.4%)20/92 (21.7%)
Sham2/89 (2.2%)16/89 (18%)23/89 (25.8%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventANX007 EMANX007 EOMSham
Atrial fibrillationCardiac disorders2/894/920/89
PneumoniaInfections and infestations3/892/920/89
Acute myocardial infarctionCardiac disorders2/891/920/89
Urinary tract infectionInfections and infestations1/891/922/89
Cerebrovascular accidentNervous system disorders2/890/922/89
EndophthalmitisInfections and infestations1/892/920/89
Angina pectorisCardiac disorders0/892/920/89
Dry age-related macular degenerationEye disorders1/890/920/89
IritisEye disorders1/890/920/89
Neovascular age-related macular degenerationEye disorders1/890/920/89
Most frequent other events
Most frequent other events
EventANX007 EMANX007 EOMSham
COVID-19Infections and infestations12/8910/9210/89
Urinary tract infectionInfections and infestations6/897/9212/89
Conjunctival haemorrhageEye disorders7/896/923/89

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)ANX007 EMANX007 EOMShamTotal
Mean79.7 ± 8.6480.5 ± 8.5379.8 ± 7.4980.0 ± 8.22
Sex: Female, Male
Sex: Female, Male(Participants)ANX007 EMANX007 EOMShamTotal
Female476059166
Male423230104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ANX007 EMANX007 EOMShamTotal
Hispanic or Latino1236
Not Hispanic or Latino888986263
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ANX007 EMANX007 EOMShamTotal
American Indian or Alaska Native0000
Asian1225
Native Hawaiian or Other Pacific Islander0101
Black or African American1001
White878987263
More than one race0000
Unknown or Not Reported0000
Study Eye GA Lesion Size
Study Eye GA Lesion Size(square millimeters (mm^2))ANX007 EMANX007 EOMShamTotal
Mean7.2789 ± 3.963427.5284 ± 4.099467.2802 ± 3.987837.3643 ± 4.00505
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity (BCVA)(Number of letters read correctly)ANX007 EMANX007 EOMShamTotal
Mean58.8 ± 17.1957.9 ± 15.3058.5 ± 16.2358.4 ± 16.19
Low-Luminance Visual Acuity (LLVA)
Low-Luminance Visual Acuity (LLVA)(Number of letters read correctly)ANX007 EMANX007 EOMShamTotal
Mean35.3 ± 16.4129.6 ± 15.7234.2 ± 18.0533.0 ± 16.86
Low-Luminance Visual Acuity Deficit (LLVD)
Low-Luminance Visual Acuity Deficit (LLVD)(Number of letters read correctly)ANX007 EMANX007 EOMShamTotal
Mean23.5 ± 16.0828.3 ± 18.3925.0 ± 15.7025.7 ± 16.86
08

Study locations

53 sites
  • Site 5
    Phoenix, Arizona 85053, United States
  • Site 31
    Bakersfield, California 93309, United States
  • Site 2
    Beverly Hills, California 90211, United States
  • Site 19
    Mountain View, California 94040, United States
  • Site 23
    Pasadena, California 91107, United States
  • Site 37
    Poway, California 92064, United States
  • Site 17
    Sacramento, California 95825, United States
  • Site 18
    Santa Ana, California 92705, United States
  • Site 33
    Walnut Creek, California 94598, United States
  • Site 39
    Waterford, Connecticut 06385, United States
  • Site 12
    Fort Myers, Florida 33907, United States
  • Site 53
    Jacksonville, Florida 32216, United States
  • Site 26
    Pensacola, Florida 32503, United States
  • Site 16
    Pinellas Park, Florida 33782, United States
  • Site 43
    Sarasota, Florida 34233, United States
  • Site 28
    St. Petersburg, Florida 33711, United States
  • Site 6
    Winter Haven, Florida 33880, United States
  • Site 42
    Augusta, Georgia 30909, United States
  • Site 11
    Lexington, Kentucky 40509, United States
  • Site 1
    Hagerstown, Maryland 21740, United States
  • Site 41
    Hagerstown, Maryland 21740, United States
  • Site 36
    Boston, Massachusetts 02114, United States
  • Site 3
    Springfield, Massachusetts 01107, United States
  • Site 29
    Royal Oak, Michigan 48073, United States
  • Site 10
    Reno, Nevada 89502, United States
  • Site 38
    Bloomfield, New Jersey 07003, United States
  • Site 9
    Cherry Hill, New Jersey 08034, United States
  • Site 30
    Albuquerque, New Mexico 87109, United States
  • Site 20
    Asheville, North Carolina 28803, United States
  • Site 52
    Cleveland, Ohio 44195, United States
  • Site 13
    Edmond, Oklahoma 73013, United States
  • Site 40
    Eugene, Oregon 97401, United States
  • Site 27
    Philadelphia, Pennsylvania 19107, United States
  • Site 15
    Abilene, Texas 79606, United States
  • Site 4
    Austin, Texas 78750, United States
  • Site 24
    Bellaire, Texas 77401, United States
  • Site 34
    Burleson, Texas 76028, United States
  • Site 21
    Dallas, Texas 75231, United States
  • Site 32
    Fort Worth, Texas 76102, United States
  • Site 22
    Fort Worth, Texas 76104, United States
  • Site 35
    Katy, Texas 77494, United States
  • Site 54
    San Antonio, Texas 78240, United States
  • Site 8
    San Antonio, Texas 78240, United States
  • Site 14
    Charlottesville, Virginia 22903, United States
  • Site 25
    Norfolk, Virginia 23502, United States
  • Site 49
    Bondi Junction, New South Wales 2022, Australia
  • Site 45
    Brookvale, New South Wales 2100, Australia
  • Site 46
    Chatswood, New South Wales 2067, Australia
  • Site 44
    Sydney, New South Wales 2000, Australia
  • Site 47
    Sydney, New South Wales 2000, Australia
  • Site 48
    Adelaide, South Australia 5000, Australia
  • Site 50
    Christchurch, 8014, New Zealand
  • Site 51
    Wellington, 6011, New Zealand
09

References and documents

Publications

  • Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. PubMed 37314061 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2023, 25 months.

Results were first posted in Oct 2026, 3 years 6 months after primary completion.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 7, 2020
StartActual
Feb 26, 2021
Primary completionActual
Mar 28, 2023
CompletionActual
Sep 13, 2023
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • Site 28 · St. Petersburg, United States
Show 1 removed
  • Site 28 · Saint Petersburg, United States
Oct 21, 2026
Eligibility
2 inclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedGA lesion must have the following characteristics as determined by the independent Central Reading Center based on assessment of FAF imaging at screening:
  • AddedCenter based on assessment of FAF imaging at screening:
  • EditedWell-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm\^2) and ≤17.5 mm\^2.
  • Added17.5 mm\^2.
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore GA lesion growth rateNow Rate of Change (Slope) From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12
Oct 21, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37314061 ↗
Oct 21, 2026
Secondary outcomes
2 edited, 6 added, 2 removed
What changed in the outcomes
  • EditedSafety:Number of Participants with treatment-emergent adverse eventsWith Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline to Month 18 → Baseline to Month 12
  • EditedChange From Baseline to Month 12 in Best corrected visual acuityCorrected Visual Acuity (BCVA)Time frame: Baseline to Month 18 → Baseline to Month 12
  • AddedChange From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12
  • AddedNumber of Events With Confirmed ≥ 15-Letter Loss BCVA DeclineTime frame: Baseline to Month 12
  • AddedChange From Baseline to Month 12 in LLVATime frame: Baseline to Month 12
  • AddedNumber of Events With ≥ 15-Letter Loss LLVA DeclineTime frame: Baseline to Month 12
  • AddedChange From Baseline to Month 12 in LLVDTime frame: Baseline to Month 12
  • AddedNumber of Events With ≥ 15-Letter Loss LLVD DeclineTime frame: Baseline to Month 12
  • RemovedLow-luminance BCVA (LL-BCVA)Time frame: Baseline to Month 18
  • RemovedLow-luminance visual acuity deficit (LL-VD)Time frame: Baseline to Month 18
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37314061 ↗
    1 site added, 1 site removed
    Show site
    • Site 28 · St. Petersburg, United States
    Show 1 removed
    • Site 28 · Saint Petersburg, United States
    Eligibility 2 inclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedGA lesion must have the following characteristics as determined by the independent Central Reading Center based on assessment of FAF imaging at screening:
    • AddedCenter based on assessment of FAF imaging at screening:
    • EditedWell-demarcated GA with a total area (baseline lesion size) ≥2.5 millimeter squared (mm\^2) and ≤17.5 mm\^2.
    • Added17.5 mm\^2.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore GA lesion growth rateNow Rate of Change (Slope) From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12
    Secondary outcomes 2 edited, 6 added, 2 removed
    What changed in the outcomes
    • EditedSafety:Number of Participants with treatment-emergent adverse eventsWith Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline to Month 18 → Baseline to Month 12
    • EditedChange From Baseline to Month 12 in Best corrected visual acuityCorrected Visual Acuity (BCVA)Time frame: Baseline to Month 18 → Baseline to Month 12
    • AddedChange From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12
    • AddedNumber of Events With Confirmed ≥ 15-Letter Loss BCVA DeclineTime frame: Baseline to Month 12
    • AddedChange From Baseline to Month 12 in LLVATime frame: Baseline to Month 12
    • AddedNumber of Events With ≥ 15-Letter Loss LLVA DeclineTime frame: Baseline to Month 12
    • AddedChange From Baseline to Month 12 in LLVDTime frame: Baseline to Month 12
    • AddedNumber of Events With ≥ 15-Letter Loss LLVD DeclineTime frame: Baseline to Month 12
    • RemovedLow-luminance BCVA (LL-BCVA)Time frame: Baseline to Month 18
    • RemovedLow-luminance visual acuity deficit (LL-VD)Time frame: Baseline to Month 18
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04656561
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Feb 26, 2021
Primary completion
Mar 28, 2023
Completion
Sep 13, 2023
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Clinical Trials
study director · Annexon, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonaprument

Start the discussion